SHINE
A randomised trial of therapy shortening for minimal tuberculosis with new WHO-recommended doses/fixed-dose-combination drugs in African and Indian HIV+ and HIV- children
Shorter treatment for minimal TB in children
What was this study about?
Tuberculosis (TB) remains one of the leading infectious causes of death among children worldwide. Each year, around 1.1 million children develop TB and an estimated 205,000 children die from the disease. Africa and Southeast Asia have the highest number of cases of TB in children, and children make up around 30% of TB cases in Africa.
Children often develop less severe forms of TB, which may not require the standard 6 months of treatment. Shortening treatment could bring major benefits for children and their families, while also reducing pressure on healthcare systems by decreasing the number of clinic visits required.
SHINE was the first large international randomised controlled trial designed to determine whether 4 months of treatment was as effective as the standard 6-month regimen for children with non-severe, drug-susceptible TB. More than 1,200 children under the age of 16 were enrolled across clinical centres in Zambia, Uganda, South Africa and India, and were followed for 72 weeks.
What difference did this study make?
The SHINE trial found that the 4-month treatment regimen was as good as the standard 6-month regimen for children with non-severe TB. There were no differences between the two groups in terms of proportion with any unfavourable clinical outcomes or deaths. Treatment -related side-effects were uncommon and occurred at similar rates in both groups.
The shorter regimen also reduced costs for healthcare systems. These findings suggest that around two thirds of children with TB could potentially be safely and effectively treated with 4 months of treatment instead of 6 months.
Based on the evidence generated by SHINE, the World Health Organization (WHO) rapidly updated its guidelines to recommend a 4-month treatment regimen for children with non-severe TB. The swift translation of the findings into global policy was supported by the trial team's ongoing engagement with WHO throughout the study.
Since the publication of the trial results and the WHO guideline update, countries and professional organisations around the world have revised their recommendations to reflect the new evidence. The SHINE findings have also led to changes in clinical practice internationally, helping more children access effective treatment with a shorter treatment duration.
SHINE paper in the NEJM journal.
SHINE impact report 2026 (pdf).
Type of study
Randomised trial
Contact details
Who funded the study?
Joint Global Health Trials Scheme of the Department for International Development, UK (DFID), the Wellcome Trust and the UK Medical Research Council (MRC UK).
When did it take place?
The trial started in July 2016 and results were published in 2022.
Where did it take place?
South Africa (Stellenbosch), Zambia (Lusaka), Uganda (Kampala) and India (Chennai and Pune).
Who was included?
Children < 16 years with suspected non-severe (limited) TB disease, with or without HIV infection.